Survival benefits of trastuzumab deruxtecan in patients with previously treated HER2-low mBC
22 May 2025
byDr. Shanu Modi, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, US; Dr. Roland Leung , Department of Medicine, University of Hong Kong
The therapeutic landscape of HER2-low metastatic breast cancer (mBC) has been transformed by the availability of trastuzumab deruxtecan (T-DXd; Enhertu®, Daiichi Sankyo & AstraZeneca), an antibody-drug conjugate (ADC). At a recent Hong Kong Breast Cancer Foundation (HKBCF) Academic Meeting, Dr Shanu Modi of Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, US, discussed the efficacy and safety of T-DXd in the phase III DESTINY-Breast04 trial. Local experiences with T-DXd were shared by Dr Roland Leung of the Department of Medicine, the University of Hong Kong.